Table 4 Univariate and multivariate survival analysis in patients with hepatocellular carcinoma undergoing RFA cohort.

Age (<65/≥65 years)

227/272

1.324

1.043–1.681

0.021

Sex (male/female)

326/173

0.836

0.647–1.055

0.126

HBsAg (negative/positive)

262/237

0.767

0.606–0.970

0.027

Anti-HCV (negative/positive)

296/203

1.083

0.855–1.372

0.510

Alcoholism (no/yes)

418/81

1.126

0.816–1.554

0.471

^aDM (no/yes)

353/143

1.188

0.922–1.530

0.183

Ascites (absent/present)

430/69

1.966

1.442–2.679

<0.001

Creatinine (<1/≥ 1 mg/dL)

266/233

1.347

1.066–1.703

0.013

ALT (≦40/>40 IU/L)

203/296

1.145

0.899–1.460

0.273

AST (≦40/>40 IU/L)

199/300

1.643

1.281–2.108

<0.001

^aAlk-P (<100/≥ 100 IU/L)

260/211

1.606

1.261–2.046

<0.001

INR of PT (<1/≥1)

127/372

1.753

1.315–2.336

<0.001

Platelet (≥150,000/<150,000/μL)

147/352

1.763

1.325–2.346

<0.001

Alpha-fetoprotein (<20/≥ 20 ng/mL)

259/240

1.4631

1.156–1.850

0.002

Tumor nodules (single/multiple)

384/115

1.235

0.945–1.614

0.123

Tumor size (≦2 cm/>2 cm)

206/293

1.541

1.206–1.968

0.001

1.635

1.269–2.106

<0.001

TTV (≦50 ml/>50 ml)

472/27

1.653

1.024–2.668

0.040

Performance status (0/1–3)

370/129

2.309

1.780–2.996

<0.001

1.788

1.349–2.369

<0.001

 Grade 1

209

1

1

 Grade 2

261

2.306

1.779–2.989

<0.001

2.352

1.786–3.098

<0.001

 Grade 3

29

5.685

3.580–8.941

<0.001

4.720

2.905–7.669

<0.001